Abstract
To the Editor: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP; EPP/XLP) are uncommon inherited heme-synthesis disorders characterized by painful cutaneous photosensitivity reactions from light-induced activation of accumulated protoporphyrin IX. Afamelanotide is the only medication with clinical effectiveness, favorable safety profile, and significantly improved EPP-specific quality of life (QoL; EPP-QoL).1,2 However, full year-round symptom control is challenging in certain subgroups because of restrictions imposed by insurance companies on dose and frequency.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
